Truist Securities has increased its price target on Gilead Sciences (GILD) to $145.00 from $140.00 and kept a Buy rating on the shares. The firm said the new target is consistent with InvestingPro’s Fair Value assessment, which continues to indicate that the stock appears slightly undervalued despite trading near its 52-week high of $138.03 and delivering a 48.54% total return over the past year.
The uplift in Truist’s target followed Gilead’s fiscal year 2025 pre-report, which included commentary on its HIV medicine Yeztugo as well as prescription trends that reflect expanding insurance coverage for the drug. Truist noted that recent prescription data and payer coverage developments influenced the adjustment.
In revising its financial model, Truist incorporated updated guidance for a number of near-term product rollouts. Those adjustments explicitly cover the expected introduction of BIC/LEN in the second half of 2025, the planned U.S. launch of Hepcludex, and additional expansion opportunities for Livdelzi. The firm also refined its assumptions for the anito-cel launch after receiving FDA guidance related to MRD negativity, while noting that potential remains for that therapy in earlier line treatment settings.
Truist said management’s public stance on the company’s immunology pipeline suggests embedded upside and prospective value inflection points for Gilead. Separately, InvestingPro assigns Gilead a financial health score of "GREAT," and highlights a moderate debt profile, a dividend yield of 2.29%, and a record of raising dividends for 11 consecutive years. The platform also notes that Gilead’s Pro Research Report and more than 14 ProTips are available to investors through InvestingPro.
Other broker activity and clinical developments were cited as additional context for investor interest. BMO Capital upgraded its target on Gilead to $150, pointing to strong momentum in the company’s HIV portfolio and the rollout of Yeztugo. The drug has secured over 80% coverage following CVS Health’s confirmation that it would begin covering Yeztugo on January 1.
Clinical data also featured prominently in recent headlines. Gilead reported Phase 3 results for a trial combining Trodelvy and Keytruda, showing a 35% reduction in the risk of disease progression or death for patients with metastatic triple-negative breast cancer.
Several other firms have maintained or adjusted their views: UBS retained a Buy rating with a $145 price target, citing Yeztugo’s early performance and noting that the drug met Gilead’s fiscal 2025 guidance of $150 million. Bernstein reiterated an Outperform rating and a $135 target, emphasizing Yeztugo’s contribution to Gilead’s 2026 growth outlook.
Together, the analyst updates, payer coverage developments, and late-stage clinical readouts underscore investor attention on Gilead’s HIV franchise and its broader pipeline of innovative therapies.
Summary
Truist Securities raised its Gilead price target to $145 and kept a Buy rating after factoring in updated guidance for several product launches and stronger prescription trends for Yeztugo. Other firms have also revised targets or maintained positive ratings amid favorable early performance and clinical results.
Key points
- Truist increased its price target to $145 from $140 and kept a Buy rating; the new target aligns with InvestingPro’s Fair Value assessment. - Markets and healthcare sectors affected.
- Model adjustments reflect updated launch timing and guidance for BIC/LEN, Hepcludex, Livdelzi, and anito-cel following FDA MRD guidance. - Impacts pharmaceutical commercialization expectations.
- Yeztugo’s expanding insurance coverage and prescription trends underpin analyst optimism; other broker notes include higher targets and reaffirmed ratings. - Relevant to payers, retail pharmacies, and biotech investors.
Risks and uncertainties
- Near-term launch timing and guidance for multiple products were adjusted - actual commercialization outcomes could differ from updated assumptions. - Affects pharmaceutical launch execution and market forecasting.
- Reimbursement and payer coverage remain in flux even as coverage expands; uptake depends on continued payer decisions and prescription trends. - Impacts health insurers and prescription volumes.
- Regulatory guidance, such as FDA direction on MRD negativity for anito-cel, prompted estimate revisions, indicating regulatory feedback can alter launch prospects and positioning. - Relates to regulatory risk in biotech.